JO3327B1 - تركيبات قرص تحتوي على المركب (z)- 2- سيانو- 3- هيدروكسي- بيوت- 2- حمض ينويك- (4'- ثالث فلورو مثيل فنيل)- أميد بمستوى ثبات محسن - Google Patents

تركيبات قرص تحتوي على المركب (z)- 2- سيانو- 3- هيدروكسي- بيوت- 2- حمض ينويك- (4'- ثالث فلورو مثيل فنيل)- أميد بمستوى ثبات محسن

Info

Publication number
JO3327B1
JO3327B1 JOP/2010/0317A JOP20100317A JO3327B1 JO 3327 B1 JO3327 B1 JO 3327B1 JO P20100317 A JOP20100317 A JO P20100317A JO 3327 B1 JO3327 B1 JO 3327B1
Authority
JO
Jordan
Prior art keywords
cyano
amide
hydroxy
trifluormethylphenyl
buty
Prior art date
Application number
JOP/2010/0317A
Other languages
English (en)
Inventor
Gerrit Hauck Dr
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41510564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3327(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of JO3327B1 publication Critical patent/JO3327B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يتعلق هذا الاختراع بتركيبات صيدلية صلبة تتضمن (Z)- 2- سيانو- 3- هيدروكسي- بيوت- 2- حمض ينويك- (4'- ثالث فلورو مثيل فنيل)- أميد، بالاضافة إلى طريقة لتحضير هذا المركب، وطرق إستخدام تلك التركيبات لعلاج الاشخاص الذين يعانون من أمراض المناعة الذاتية وعلى وجه الخصوص الذئبة الحمراء أو الامراض المزمنة التي تحدث بسبب تفاعلات العضو المزروع بداخل العائل، التصلب المتعدد أو الالتهاب الروماتيزمي للمفاصل.
JOP/2010/0317A 2009-09-18 2010-09-16 تركيبات قرص تحتوي على المركب (z)- 2- سيانو- 3- هيدروكسي- بيوت- 2- حمض ينويك- (4'- ثالث فلورو مثيل فنيل)- أميد بمستوى ثبات محسن JO3327B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09290716 2009-09-18

Publications (1)

Publication Number Publication Date
JO3327B1 true JO3327B1 (ar) 2019-03-13

Family

ID=41510564

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0317A JO3327B1 (ar) 2009-09-18 2010-09-16 تركيبات قرص تحتوي على المركب (z)- 2- سيانو- 3- هيدروكسي- بيوت- 2- حمض ينويك- (4'- ثالث فلورو مثيل فنيل)- أميد بمستوى ثبات محسن

Country Status (42)

Country Link
US (5) US20120172427A1 (ar)
EP (1) EP2477611B1 (ar)
JP (1) JP2013505213A (ar)
KR (1) KR101547880B1 (ar)
CN (4) CN104666272A (ar)
AR (1) AR078383A1 (ar)
AU (2) AU2010297357B2 (ar)
BR (1) BR112012006184B1 (ar)
CA (1) CA2772275A1 (ar)
CL (1) CL2015000047A1 (ar)
CO (1) CO6511244A2 (ar)
CR (2) CR20170078A (ar)
CY (1) CY1119364T1 (ar)
DK (1) DK2477611T3 (ar)
DO (1) DOP2012000070A (ar)
ES (1) ES2625731T3 (ar)
GT (1) GT201200075A (ar)
HK (1) HK1206244A1 (ar)
HN (1) HN2012000576A (ar)
HR (1) HRP20170904T1 (ar)
HU (1) HUE032963T2 (ar)
IL (3) IL218492A (ar)
JO (1) JO3327B1 (ar)
LT (1) LT2477611T (ar)
MA (1) MA33585B1 (ar)
ME (1) ME02765B (ar)
MX (1) MX336663B (ar)
MY (1) MY155613A (ar)
NZ (2) NZ617025A (ar)
PE (2) PE20152031A1 (ar)
PL (1) PL2477611T3 (ar)
PT (1) PT2477611T (ar)
PY (1) PY1038455A (ar)
RS (1) RS56074B1 (ar)
RU (2) RU2012115459A (ar)
SI (1) SI2477611T1 (ar)
SM (1) SMT201700299T1 (ar)
TN (1) TN2012000061A1 (ar)
TW (2) TWI522130B (ar)
UA (2) UA107582C2 (ar)
UY (1) UY32889A (ar)
WO (1) WO2011032929A1 (ar)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120172427A1 (en) * 2009-09-18 2012-07-05 Sanofi (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide tablet formulations with improved stability
RU2493845C1 (ru) * 2012-06-07 2013-09-27 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Композиция для лечения рассеянного склероза (варианты)
EP3071199A2 (en) * 2013-11-22 2016-09-28 Genzyme Corporation Novel methods for treating neurodegenerative diseases
CN103656657A (zh) * 2013-12-18 2014-03-26 北京科源创欣科技有限公司 特立氟胺药物组合物及制备方法
JP6752715B2 (ja) 2014-03-26 2020-09-09 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 組合せ
US20160058730A1 (en) * 2014-08-29 2016-03-03 Cadila Healthcare Limited Pharmaceutical compositions of teriflunomide
WO2016079687A1 (en) * 2014-11-18 2016-05-26 Lupin Limited Oral pharmaceutical composition of teriflunomide
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
WO2016189406A1 (en) 2015-05-23 2016-12-01 Ftf Pharma Private Limited Pharmaceutical composition of teriflunomide
WO2017037022A1 (en) * 2015-09-01 2017-03-09 Bayer Pharma Aktiengesellschaft Compounds and methods useful for treating or preventing hematological cancers
WO2017037645A1 (en) * 2015-09-02 2017-03-09 Leiutis Pharmaceuticals Pvt Ltd Stable pharmaceutical formulations of teriflunomide
WO2017056104A1 (en) * 2015-09-28 2017-04-06 Natco Pharma Limited Stable pharmaceutical compositions of teriflunomide
WO2017125841A1 (en) * 2016-01-20 2017-07-27 Emcure Pharmaceuticals Limited Pharmaceutical compositions of teriflunomide
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
HRP20240200T1 (hr) * 2019-07-17 2024-04-26 Cytokinetics, Inc. Oralne formulacije inhibitora kardijskih sarkomera
US12472176B2 (en) * 2020-07-07 2025-11-18 Celgene Corporation Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
WO2022085015A1 (en) * 2020-10-24 2022-04-28 V-Ensure Pharma Technologies Private Limited A solid oral composition of teriflunomide
GR1010137B (el) 2020-12-15 2021-12-07 Φαρματεν Α.Β.Ε.Ε., Στερεη φαρμακοτεχνικη μορφη αμεσης αποδεσμευσης περιεχουσα τεριφλουνομιδη και μεθοδος παρασκευης αυτης
TR202022336A2 (tr) * 2020-12-30 2022-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A film coated tablet comprising teriflunomide
TR2022017840A1 (tr) * 2022-11-25 2024-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Teri̇flunomi̇d i̇çeren bi̇r tablet
EP4382097A1 (en) 2022-11-25 2024-06-12 Sanovel Ilac Sanayi Ve Ticaret A.S. A tablet comprising teriflunomide

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852294A (en) * 1968-08-27 1974-12-03 Merck Patent Gmbh Bis-quaternary pyridinium salts
DE3534440A1 (de) 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US5268382A (en) * 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
US6133301A (en) 1991-08-22 2000-10-17 Aventis Pharma Deutschland Gmbh Pharmaceuticals for the treatment of rejection reactions in organ transplantations
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
KR100365064B1 (ko) 1994-10-17 2003-04-11 훽스트파마슈티칼스앤드케미칼스가부시키가이샤 I형알레르기성질환의예방및치료제
ATE196764T1 (de) 1997-08-08 2000-10-15 Aventis Pharma Gmbh Kristallform von 5-methylisoxazol-4-carbonsäure- (4-trifluormethyl)-anilid
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2400290A1 (en) 2000-02-15 2001-08-23 Teva Pharmaceutical Industries Ltd. A method for synthesizing leflunomide
EP1381356B1 (en) 2001-04-05 2008-05-28 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
GB0123571D0 (en) * 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US20050158371A1 (en) 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
US20050070608A1 (en) * 2003-08-29 2005-03-31 Julius Remenar Pharmaceutical compositions and method of using levodopa and carbidopa
GB2394660A (en) 2003-12-17 2004-05-05 Niche Generics Ltd Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide
US20050220874A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate release and controlled release properties that contain a GABAB receptor agonist
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
CA2584655A1 (en) * 2004-10-19 2006-04-27 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
TWI275029B (en) * 2005-11-18 2007-03-01 Hon Hai Prec Ind Co Ltd An embedded system and method for processing data thereof
WO2007086891A1 (en) 2006-01-24 2007-08-02 Teva Pharmaceutical Industries Ltd. Levetiracetam formulations and methods for their manufacture
DE102006017896A1 (de) * 2006-04-13 2007-10-25 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Leflunomid enthaltende pharmazeutische Zusammensetzungen
EP1990048A3 (en) 2007-05-08 2009-05-06 Ulrike Wiebelitz Therapy of benign prostatic hyperplasia (bph)
US20120172427A1 (en) * 2009-09-18 2012-07-05 Sanofi (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide tablet formulations with improved stability
EP2762135A1 (en) * 2013-02-04 2014-08-06 Sanofi Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients

Also Published As

Publication number Publication date
AU2010297357B2 (en) 2013-11-07
US20170247319A1 (en) 2017-08-31
JP2013505213A (ja) 2013-02-14
TW201117838A (en) 2011-06-01
US20140235888A1 (en) 2014-08-21
BR112012006184A2 (pt) 2016-05-31
CN102596184A (zh) 2012-07-18
TWI522130B (zh) 2016-02-21
ES2625731T3 (es) 2017-07-20
AU2010297357A1 (en) 2012-04-05
LT2477611T (lt) 2017-06-26
BR112012006184B1 (pt) 2022-10-18
UY32889A (es) 2011-04-29
US20190241505A1 (en) 2019-08-08
US20120172427A1 (en) 2012-07-05
ME02765B (me) 2018-01-20
IL264912B (en) 2019-11-28
CN104666238B (zh) 2018-04-06
TN2012000061A1 (en) 2013-09-19
CY1119364T1 (el) 2018-02-14
CL2015000047A1 (es) 2015-06-12
SI2477611T1 (sl) 2017-07-31
DK2477611T3 (en) 2017-07-10
PE20152031A1 (es) 2016-01-14
CR20120116A (es) 2012-06-15
CN102596184B (zh) 2015-03-11
WO2011032929A1 (en) 2011-03-24
CN104666238A (zh) 2015-06-03
IL244809B (en) 2019-03-31
HUE032963T2 (en) 2017-11-28
PT2477611T (pt) 2017-06-05
HRP20170904T1 (hr) 2017-09-08
US8802735B2 (en) 2014-08-12
IL218492A (en) 2016-04-21
RS56074B1 (sr) 2017-10-31
KR101547880B1 (ko) 2015-08-27
UA107582C2 (uk) 2015-01-26
UA115979C2 (uk) 2018-01-25
EP2477611B1 (en) 2017-04-05
MA33585B1 (fr) 2012-09-01
NZ617025A (en) 2014-03-28
AU2013257516B2 (en) 2015-09-17
CO6511244A2 (es) 2012-08-31
CN104739821A (zh) 2015-07-01
CA2772275A1 (en) 2011-03-24
SMT201700299T1 (it) 2017-07-18
AR078383A1 (es) 2011-11-02
RU2681079C2 (ru) 2019-03-04
TW201517935A (zh) 2015-05-16
MX336663B (es) 2016-01-27
DOP2012000070A (es) 2012-05-31
RU2015151938A (ru) 2019-01-15
PY1038455A (es) 2014-07-01
IL218492A0 (en) 2012-04-30
TWI468190B (zh) 2015-01-11
PE20121478A1 (es) 2012-11-12
RU2012115459A (ru) 2013-10-27
EP2477611A1 (en) 2012-07-25
CR20170078A (es) 2017-05-22
CN104666272A (zh) 2015-06-03
RU2015151938A3 (ar) 2019-01-15
US20120208880A1 (en) 2012-08-16
HK1206245A1 (en) 2016-01-08
MX2012003122A (es) 2012-04-10
HK1206244A1 (en) 2016-01-08
HN2012000576A (es) 2015-01-26
KR20120089461A (ko) 2012-08-10
CN104739821B (zh) 2018-04-06
IL244809A0 (en) 2016-04-21
NZ598744A (en) 2013-11-29
PL2477611T3 (pl) 2017-09-29
MY155613A (en) 2015-11-13
GT201200075A (es) 2014-05-14

Similar Documents

Publication Publication Date Title
JO3327B1 (ar) تركيبات قرص تحتوي على المركب (z)- 2- سيانو- 3- هيدروكسي- بيوت- 2- حمض ينويك- (4'- ثالث فلورو مثيل فنيل)- أميد بمستوى ثبات محسن
MX2009005398A (es) Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf.
NZ606587A (en) Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
MX2012007273A (es) Pteridinonas como inhibidores de la quinasa tipo polo.
EA201100524A1 (ru) Азаиндазолы в качестве антагонистов рецептора ccr1
EP3363797A8 (en) Oral dosage form of apoptosis signal-regulating kinase inhibitors
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
NZ712479A (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
WO2012048129A3 (en) Inhibitors of polo-like kinase
MA32898B1 (ar) مغيرات تفارغية إيجابية لمستقبلات أريلميثيلبينزوكوينازولينون
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
EP2582676A4 (en) POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
IN2014CN02364A (ar)
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
MX2010002407A (es) Cocristales y composiciones farmaceuticas que los comprenden.
WO2008079610A3 (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
SG158091A1 (en) Imidazoazepinone compounds
EA201300826A1 (ru) Применение димирацетама для лечения остеоартрита и связанных с ним заболеваний
FR2981936B1 (fr) Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
EA201590790A1 (ru) СТАБИЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ PEG-ИНТЕРФЕРОНА АЛЬФА-2b
DE602007007934D1 (en) Imidazoazephinonverbindungen
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.